B of A Securities raises Humana price target to $380
B of A Securities analyst Kevin Fischbeck maintained a Neutral rating on Humana (NYSE: HUM) and raised the price target to $380 from $340.

*this image is generated using AI for illustrative purposes only.
B of A Securities analyst Kevin Fischbeck has maintained a Neutral rating on Humana (NYSE: HUM) and increased the price target to $380 from $340. The adjustment reflects a revised valuation outlook for the healthcare company.
The revised target suggests a potential upside based on the previous closing price, though the firm remains cautious on the stock's near-term trajectory. The Neutral stance indicates that the stock is expected to perform in line with the broader market.
| Metric | Value |
|---|---|
| Rating | Neutral |
| Previous Price Target | $340 |
| New Price Target | $380 |
Investors will monitor Humana's upcoming earnings and operational updates to gauge if the company can meet the revised expectations set by B of A Securities.
What specific operational factors could drive Humana's stock to meet the new $380 price target?
How might upcoming earnings reports influence B of A Securities' Neutral rating?
What risks could prevent Humana from achieving the revised valuation outlook?





























